Plain-English translation of NCT07188610 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
PA3-17 injection is an experimental CAR-T cell therapy — a treatment made from your own immune cells that have been engineered in the laboratory to recognize and fight cancer cells. This trial is testing whether this medication can help adults whose T-cell blood cancer has returned or stopped responding to other treatments. You would receive a single infusion of these specially prepared cells after a brief chemotherapy preparation.
Some patients with aggressive T-cell blood cancers don't respond well to standard treatments, or their cancer comes back after treatment. This medication aims to offer a new option for people in that difficult situation by training the immune system to attack the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would have your blood cells collected in an outpatient procedure, which are then sent to a laboratory to be engineered into the treatment medication. After this, you would receive a brief chemotherapy regimen to prepare your body, followed by a single infusion of the engineered cells. You would then return for check-ups at 4 weeks, 2 months, 3 months, and every 3 months after that for up to 2 years, with blood tests and imaging scans to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China